UPDATE: Gilead to Stop Phase 3 Study 116 of Idelalisib in Chronic Lymphocytic Leukemia Early Because of Positive Risk-Benefit
October 09, 2013 at 16:20 PM EDT
Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences (Nasdaq: GILD ) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early. This DMC recommendation is based
